舒尼替尼与索拉非尼治疗晚期肝细胞癌的效果对比研究

A comparative study of sunitinib and sorafenib in the treatment of advanced hepatocellular carcinoma

目的对比舒尼替尼与索拉非尼治疗晚期肝细胞癌的临床价值。方法研究时段为2018年5月~2019年8月,研究对象为烟台市莱阳中心医院肿瘤内科接收的72例晚期肝细胞癌患者,遵从药物差异分组原则,将其分为对照组(35例,口服索拉非尼治疗)和观察组(37例,口服舒尼替尼治疗),观察临床疗效、治疗不同时段患者活动能力、生活质量改善情况以及不良反应发生率。结果①观察组临床疗效显著高于对照组(P<0.05)。②经治疗后观察组患者治疗后不同时段活动能力评分、生活质量评分高于对照组(P<0.05)。③观察组不良反应发生率显著低于对照组(P<0.05)。结论对晚期肝细胞癌患者实施药物治疗,建议以舒尼替尼为主,在提高临床疗效、改善患者活动能力和生活质量的同时可有效降低不良反应发生率。

Objective To compare the clinical value of sunitinib and sorafenib in the treatment of advanced hepatocellular carcinoma.Methods The study period was from May 2018 to August 2019.72 patients with advanced hepatocellular carcinoma received in the Department of oncology of our hospital were divided into control group(35 cases,oral sorafenib treatment)and observation group(37 cases,oral sunitinib treatment)according to the principle of drug difference grouping.Observe the clinical efficacy,the ability of patients to move in different periods of treatment,the improvement of quality of life and the incidence of adverse reactions.Results①The clinical efficacy of the observation group was significantly higher than that of the control group(P<0.05).②After treatment,the activity ability score and quality of life score of the observation group were higher than those of the control group(P<0.05).③The incidence of adverse reactions in the observation group was significantly lower than that in the control group(P<0.05).Conclusion Sunitinib is recommended as the main treatment for patients with advanced hepatocellular carcinoma,which can improve the clinical efficacy,activity ability and quality of life of patients,and effectively reduce the incidence of adverse reactions.